MedPath

Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate

Completed
Conditions
Rheumatic Diseases
Registration Number
NCT04042792
Lead Sponsor
University Hospital, Basel, Switzerland
Brief Summary

This study is to assess standardized Adalimumab (ADA) concentrations in Pediatric inflammatory rheumatic diseases (PiRD) patients treated with ADA for ≥ 12 weeks with and without concomitant methotrexate (MTX) therapy and to assess peak and trough ADA concentrations in ADA naïve patients after first ADA administration with and without MTX (pre-phase).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Confirmed diagnosis of a juvenile idiopathic Arthritis (JIA), uveitis or chronic recurrent multifocal osteomyelitis (CRMO)
  • Medical indication for initiation of ADA treatment or established ADA therapy for ≥ 12 weeks
  • Exclusion of chronic infections
  • No parallel treatment with other biologic medications
  • Available patient history since ADA start
  • No pregnancy
  • Ability to comply with the entire study protocol
  • Willingness to participate with signed informed consent
Exclusion Criteria
  • Other rheumatic inflammatory diseases
  • Age < 2 years or >18 years
  • PiRD patients and parents with cognitive impairments preventing to understand study requirements
  • Additional severe chronic disease (kidney failure, liver insufficiency), malignancies or prior chemotherapy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ADA concentration (in mg/L)during regular clinical follow up 3-6 months after inclusion

ADA concentration (in mg/L)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

University Children's Hospital Tubingen

🇩🇪

Tübingen, Germany

University of Basel Children's Hospital

🇨🇭

Basel, Switzerland

University Children's Hospital Tubingen
🇩🇪Tübingen, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.